Biomerieux SA operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biomerieux SA with three other
pharmaceutical manufacturers in Europe:
Stada Arzneimittel AG
sales of 2.33 billion Euro [US$2.58 billion]
of which 59%
(2.35 billion Euro [US$2.60 billion]
of which 82%
was Specialty Care), and
H. Lundbeck A/S
based in Denmark
(18.12 billion Danish Kroner [US$2.69 billion]
of which 100%
Biomerieux SA reported sales of 2.42 billion Euro (US$2.68 billion)
December of 2018.
increase of 5.8%
versus 2017, when the company's sales were 2.29 billion Euro.
Sales at Biomerieux SA have increased during each of the previous five years
(and since 2013, sales have increased a total of 52%).
Sales of Diagnostic Clinical Equipment saw an increase
7.4% in 2018, from
1.85 billion Euro to 1.99 billion Euro.